RCM
AIMT

RA Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

RA Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-677,663
Closed -$13.9M – 31
2016
Q4 		$13.9M Sell
677,663
-615,277
-48% -$12.6M 1.96% 13
2016
Q3 		$19.4M Hold
1,292,940
– – 2% 12
2016
Q2 		$14M Hold
1,292,940
– – 1.94% 12
2016
Q1 		$17.5M Buy
1,292,940
+502,740
+64% +$7.84M 2.24% 13
2015
Q4 		$14.6M Hold
790,200
– – 1.44% 23
2015
Q3 		$20M Buy
+790,200
New +$18.5M 2.87% 12

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RA Capital Management's AIMT Position: Q1 2017 in Review

RA Capital Management sold out of Aimmune Therapeutics (AIMT) in Q1 2017, closing a stake of 677,663 shares — an estimated $13.9M sold.

RA Capital Management first reported a position in AIMT in Q3 2015 and held it in 6 quarters. The position peaked at $20M in Q3 2015. 90 funds tracked by Wall St. Rank hold AIMT as of Q1 2017.

  • RA Capital Management reported no remaining Aimmune Therapeutics position as of Q1 2017 after selling out during the quarter.
  • RA Capital Management sold 677,663 Aimmune Therapeutics shares in Q1 2017, an estimated $13.9M.
  • RA Capital Management first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 6 quarters.
  • RA Capital Management's Aimmune Therapeutics position peaked at $20M in Q3 2015.
  • 90 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2017.

Based on RA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.